Wiviott, S. Et Al. 2019. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine , vol.380, no.4 , 347-357.

Wiviott, S., Raz, I., Bonaca, M., Mosenzon, O., Kato, E., Cahn, A., ... Silverman, M.(2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine , vol.380, no.4, 347-357.

Wiviott, S.D. Et Al. "Dapagliflozin and cardiovascular outcomes in type 2 diabetes," New England Journal of Medicine , vol.380, no.4, 347-357, 2019

Wiviott, S.D. Et Al. "Dapagliflozin and cardiovascular outcomes in type 2 diabetes." New England Journal of Medicine , vol.380, no.4, pp.347-357, 2019

Wiviott, S. Et Al. (2019) . "Dapagliflozin and cardiovascular outcomes in type 2 diabetes." New England Journal of Medicine , vol.380, no.4, pp.347-357.

@article{article, author={S.D. Wiviott Et Al. }, title={Dapagliflozin and cardiovascular outcomes in type 2 diabetes}, journal={New England Journal of Medicine}, year=2019, pages={347-357} }